Higher global quality of life and less severe symptoms were found with carboplatin-based when compared with cisplatinbased chemotherapy in patients with advanced non-small cell lung cancer who received palliative chemotherapy. Survival rates did not differ. Limitations in reported process, the small number of included trials and uncertain trial quality make the reliability of the authors' conclusions unclear.
Authors' objectives
To assess the effect of palliative chemotherapy in patients with advanced non-small cell lung cancer on quality of life in addition to overall survival and disease-related symptoms in order to help inform selection of suitable chemotherapy regimen.
Searching
PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched up to April 2010; search terms were reported. Reference lists were searched. Only publications in English were considered.
Study selection
Eligible studies were randomised controlled phase III trials (RCTs) that compared carboplatin-based to cisplatin-based chemotherapy in patients with pathologically confirmed advanced non-small cell lung cancer who had not previously received chemotherapy. Trials needed to report quality of life data and were required to provide longitudinal as well as explicit quality of life data measured using the European Organization for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) or the Functional Assessment of Cancer Therapy-Lung (FACT-L).
Trials that compared outcomes with a historical or literature arm were excluded. Trials that did not report adequate information of the clinical assessment of the main outcomes and the randomisation process were excluded.
Quality of life outcomes focused on global quality of life and key symptom domains (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Cisplatin-based chemotherapy arms included cisplatin plus paclitaxel, gemcitabine, vinorelbine or mitomycin (plus ifosfamide or vinblastine) administered every three to four weeks. Carboplatin-based chemotherapy arms included carboplatin plus paclitaxel, gemcitabine, docetaxel or mitomycin plus vinblastine administered every three or four weeks.
The authors did not state how many reviewers were involved in trial selection.
Assessment of study quality
The authors did not state that they formally assessed the quality of the included trials.
Data extraction
Estimates of effect for quality of life were to be extracted or calculated for each trial. Estimates of effect size could not be obtained for any of the included trials so one sided p-values were calculated from the two-sided p-values obtained from the published studies under the hypothesis of a favourable outcome for carboplatin-based chemotherapy. When the p-value for the difference between regimens was not provided it was calculated with a t-test using difference in quality of life scores for each regimen. In trials that did not report estimates or sufficient data to calculate estimates, a combination of all estimates (positive and negative) were assumed and corresponding one-sided p-values for all cases were calculated. Only quality of life data collected at baseline and between 12 and 17 weeks following the start of treatment were used. Relative risks and associated 95% confidence intervals (CIs) were extracted for survival and response rates. Authors were contacted for data confirmation.
